Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

8/19/24 12:12:51 PM ET

Other Consumer Services

Consumer Discretionary

Get the next $APDN alert in real time by email

SC 13G/A 1 apdn13ga4.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 4)* Applied DNA Sciences, Inc. -------------------------------------------------------------------- (Name of Issuer) Common Stock ------------------------------------------------------------------ (Title of Class of Securities) 03815U409 ---------------------------------------------------------------------- (CUSIP Number) 08/19/2024 ---------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: /X/ Rule 13d-i(b) / / Rule 13d-i(c) / / Rule 13d-i(d) ------------------------ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP NO. 03815U409 13G/A ------------------------------------------------------------------------ -------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) AMH Equity LLC ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------- OWNED BY 6 SHARED VOTING POWER EACH ------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 WITH ------------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.00% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* PN ------------------------------------------------------------------------ CUSIP NO. 03815U409 13G/A ------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Leviticus Partners, L.P. ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 0 Shares of Common Stock BENEFICIALLY ------------------------------------------ OWNED BY 6 SHARED VOTING POWER EACH ----------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 Shares of Common Stock WITH --------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.00% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IA ------------------------------------------------------------------------ ITEM 1: (a) NAME OF ISSUER: Applied DNA Sciences, Inc. (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 50 Health Sciences Drive Stony Brook, New York 11790 ITEM 2: (a) NAME OF PERSON FILING: This Schedule 13G/A is jointly filed by Leviticus Partners, L.P., a Delaware limited partnership ("Leviticus"), and AMH Equity, LLC ("AMH"), a New York limited liability company (each a "Reporting Person" and, collectively, the "Reporting Persons"). AMH is the general partner of Leviticus. (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE : 32 Old Mill Road Great Neck, NY 11023 (c) CITIZENSHIP: See above (d) TITLE OF CLASS OF SECURITIES: SEE COVER PAGE (e) CUSIP NUMBER: SEE COVER PAGE ITEM 3: See Item 12 above ITEM 4: (a) AMOUNT BENEFICIALLY OWNED: See Item 9 above (b) PERCENT OF CLASS: See Item 11 above (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS VOTING AND DISPOSITIVE POWERS: See Items 5 and 7 above ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: /X/ ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: N/A The principal address of Leviticus is: 32 Old Mill Road Great Neck, NY 11023 ITEM 7: Inapplicable ITEM 8: Inapplicable ITEM 9: NOTICE OF DISSOLUTION OF GROUP: Inapplicable ITEM 10: CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in theordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: August 19, 2024 Leviticus Partners, L.P. By: AMH Equity, LLC, its general partner By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member AMH Equity, LLC By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member

Get the next $APDN alert in real time by email

Date

Price Target

Rating

Analyst

2/11/2022

$8.00 → $6.00

Buy

HC Wainwright & Co.

8/13/2021

$13.00 → $11.00

Buy

HC Wainwright & Co.

Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

8/19/24 12:12:51 PM ET

$APDN

Other Consumer Services

Consumer Discretionary

Get the next $APDN alert in real time by email

Date

Price Target

Rating

Analyst

2/11/2022

$8.00 → $6.00

Buy

HC Wainwright & Co.

8/13/2021

$13.00 → $11.00

Buy

HC Wainwright & Co.

Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$APDN

Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$APDN

$APDN
Press Releases

Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

$APDN
Analyst Ratings

HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

$APDN
SEC Filings

Applied DNA Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits

Applied DNA Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Applied DNA Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Other Events

$APDN
Insider Trading

SEC Form 4 filed by Jantzen Beth

SEC Form 4 filed by Shorrock Clay

SEC Form 4 filed by Murrah Judith

$APDN
Large Ownership Changes

SEC Form SC 13G filed by Applied DNA Sciences Inc.